移植后血小板减少症的危险因素与发病机制研究现状

Research status on the risk factors and pathogenesis of thrombocytopenia after transplantation

移植后血小板减少症是造血干细胞移植(HSCT)的常见并发症之一,可使患者出血风险增高,预后不良。由于移植后血小板减少症的危险因素及发病机制迄今尚未完全阐明,因此对移植后血小板减少症尚无标准治疗方案,常采用输注血小板支持治疗措施,但是该措施存在一定临床局限性。针对移植后血小板减少症的有效治疗药物迄今尚在不断研发中,而深入研究移植后血小板减少症的相关危险因素及发病机制,可对患者采取针对性预防措施及有效治疗方法,对降低该病发生率和出血风险、改善患者预后具有重要临床意义。笔者拟就移植后血小板减少症的危险因素和发病机制的最新研究现状进行阐述,旨在为临床对该病防治提供参考。

Post-transplant thrombocytopenia is a common complication of hematopoietic stem cell transplantation(HSCT),resulting in an increased risk of organic bleeding and a poor prognosis for patients.Because the risk factors and pathogenesis have not been clearly elaborated,there is no standard treatment for this disease,and platelet transfusion is often used to support treatment,but there are some clinical limitations.Effective therapeutic drugs for post-transplantation thrombocytopenia are constantly being explored,and in-depth study of its risk factors and pathogenesis to find targeted preventive measures and effective treatments has important clinical significance in reducing the incidence of the disease and the risk of hemorrhage,as well as improving the prognosis of patients.This article elaborates on the current research status of risk factors and pathogenesis of post-transplant thrombocytopenia,aiming to provide reference for the prevention and treatment of this disease.